drugset
drugset / Trial / NCT04693455

ZD03 Capsule Study

NCT04693455 ↗

Phase 1 Completed 48 enrolled Shanxi Zhendong Leading Biotechnology Co., Ltd.
RandomizedSequentialDouble-blindTreatment

Summary

This is a Phase 1, Double Blind, Randomized, Placebo Controlled, Single Dose, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZD03 Capsule in Healthy Volunteers in The United States

Timeline

Start
2019-11-06
Primary completion
2020-04-27
Completion
2020-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject ZD03 Small molecule 20 mg Oral
Subject ZD03 Small molecule 40 mg Oral
Subject ZD03 Small molecule 80 mg Oral
Subject ZD03 Small molecule 120 mg Oral
Subject ZD03 Small molecule 180 mg Oral
Subject ZD03 Small molecule 240 mg Oral
Subject ZD03 Small molecule 300 mg Oral

Indications

No indication recorded.